In this episode of The BioHub Podcast, Max sits down with Cary Claiborne, CEO of Adial Pharmaceuticals.
Cary’s career spans finance, M&A, and leadership across multiple public biotech companies before stepping into the CEO role at Adial. The company is focused on developing genetically targeted therapies for addiction, starting with alcohol use disorder.
In this conversation, Cary shares his transition into biotech leadership, what it’s like running a micro-cap clinical-stage company, and how Adial is approaching one of the most complex and underserved areas in medicine.
They also discuss leadership, resilience, and the realities of building and financing biotech companies in today’s market.
The BioHub: The Top Voices in Biotech